ONCY - Oncolytics Biotech jumps 9% on positive data for breast cancer candidate

Oncolytics Biotech (NASDAQ:ONCY) gains 9.2% premarket after announcing a positive interim safety update from phase 2 IRENE trial at the 2021 San Antonio Breast Cancer Symposium (SABCS). The IRENE trial is designed to evaluate the safety and efficacy of pelareorep in combination with Incyte's (NASDAQ:INCY) retifanlimab for second- or third-line treatment of patients with metastatic triple-negative breast cancer (TNBC). The combination was well-tolerated, with no safety concerns noted in any of the five patients enrolled in the trial. The trial remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center. The co-primary endpoints of the study are safety and objective response rate. Secondary endpoints include progression-free survival, overall survival, and duration of response. Exploratory endpoints include peripheral T cell clonality and pre- vs. post-treatment change in tumor PD-L1 expression.

For further details see:

Oncolytics Biotech jumps 9% on positive data for breast cancer candidate